NPLATE® (Romiplostim)

The FDA on December 14, 2018 approved NPLATE® for pediatric patients 1 year of age and older with Immune Thrombocytopenia (ITP) for at least 6 months, who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. NPLATE® is a product of Amgen Inc.